Wellness
Science edges towards breakthrough in male contraception

After decades of women carrying contraceptive responsibility, advancements in the development of male contraceptives could see products approved for use within the next few years, with the potential to shift the burden of birth control.
For all the freedoms that come with it, for decades, women have borne the brunt of the responsibility for birth control, subjecting themselves to painful medical procedures and hormonal side effects, all to avoid unwanted pregnancy.
There are significantly fewer options when it comes to contraception for men, who are limited to using condoms or, at the other end of the extreme, undergoing a vasectomy.
But the field is on the cusp of transformation, with new advancements in male contraceptives that could rebalance the burden of birth control and give men a more active role in family planning.
First FDA-approved hormonal contraceptive for men
Scientists at biotech company Contraline are behind two advanced-stage innovations taking different approaches to male contraception, both of which are currently progressing through clinical trials.
Its lead candidate, NES/T – a transdermal gel that combines nestorone and testosterone to suppress sperm production – is said to be the most advanced male contraceptive currently in development and is poised to become the first FDA-approved hormonal contraceptive for men.
Applied daily to the user’s shoulders, it systemically delivers the two exogenous hormones to reduce sperm count, while balancing the serum hormones, such as testosterone, of the patient to minimise side-effects.
A Phase 2b study on NES/T, led by the Population Council and the NICHD, on over 400 couples, most of whom used the gel for around 18 months, showed “encouraging efficacy in suppressing sperm levels to contraceptive thresholds, along with a favourable safety profile,” Kevin Eisenfrats, co-founder and CEO of Contraline, tells Femtech World.
“We believe NES/T will be transformational in getting men excited about using contraception.”
Full results from the trial are expected to be published later this year, and in July, Contraline announced its decision to exercise its exclusive option agreement to license NES/T from the Population Council.
A Phase 3 trial is expected to launch in 2026 to pave the way for regulatory approval within the next few years.
Eisenfrats described this as a “pivotal moment” not just for Contraline, but for the “future of contraception”.
“We’re proud to build on the decades of groundbreaking work by the Population Council and NICHD and carry this momentum into Phase 3 and beyond,” he said in a statement at the time.
“Long-acting, reversible birth control”
In the meantime, Contraline is also developing an alternative to the vasectomy in the form of ADAM, billed as the world’s first injectable hydrogel designed to provide long-lasting, non-hormonal, and reversible contraception for men.
Injected into the vas deferens, the same duct targeted during a vasectomy, the gel forms a “soft, flexible barrier” that blocks sperm rather than cutting or permanently sealing it. While NES/T works systemically and requires consistent application, ADAM is localised and takes a set-it-and-forget-it approach. Compared to hormonal methods, it simply blocks sperm in the vas, meaning the user won’t experience any systemic side effects.
Crucially, unlike a vasectomy, ADAM is not permanent, but is designed to last up to two years and be easily reversible.
The hydrogel degrades naturally after this time, mirroring the concept of how intrauterine devices (IUDs) are used in women. Contraline has also designed a ‘minimally invasive’ reversal procedure to remove the implant and restore fertility before its two-year lifespan, which has been tested in pre-clinical models and is set to be incorporated into upcoming trials.
The results from its first in-human clinical trial of ADAM, were published in April, demonstrating both safety and efficacy, with no treatment-related serious adverse events reported, and Contraline has now received full regulatory approval to initiate a Phase 2 (Early Feasibility) clinical study in Australia later this year.
While not intended to replace the role of condoms in protecting against STIs, ADAM could reduce dependence on hormonal birth control and is expected to have fewer side effects than female options such as IUDs.
“ADAM fills a major gap: it offers men a long-acting, reversible form of birth control that simply doesn’t exist today,” Eisenfrats says
“It also complements female contraception in couples who want to share responsibility. There is a strong chance that the ADAM procedure could have fewer side effects and, therefore, be more appealing than IUDs for women, especially given that most IUDs are hormonal.
Shifting the burden of responsibility
Beyond the medical potential of products like ADAM and NES/T, these developments in male contraceptives could pave the way for a cultural shift in how we think about contraception.
“ADAM opens the door for a fundamental shift in how we think about contraceptive responsibility,” says Eisenfrats.
“Historically, the burden has disproportionately fallen on women. This relieves some of the burden placed on women, while empowering men to be great partners and take an active role.
He adds: “Male contraception will also be an option for couples where the female can’t be on hormonal birth control. By enabling men to step forward with a long-acting, non-hormonal option, we help drive the larger goal of gender equity in family planning.”
Such significant shifts in societal attitudes take time, though, and for real change to happen, men will have to be willing to play a more active role in sharing the contraceptive load.
Contraline is keen to play a part in this, building a strategy around “open conversation, education and storytelling”.
“This means meeting people where they are, whether that’s online, in clinics, or through partnerships with healthcare providers,” he says.
“Our approach emphasises shared responsibility, not just a shift from one partner to another. It’s about creating a new narrative that contraception can and should be a mutual decision, and that men have a role to play in protecting their partner’s health and their own future.”
Promisingly, there has been “overwhelming interest” from men and their partners coming forward to participate in clinical trials, with over 19,000 currently on Contraline’s waiting list, Eisenfrats says. While in Australia, 1,500 men came forward to take part in a trial with only 25 places.
“The enthusiasm and demand we have seen from the patients and investigators involved in the trials have been unmistakable,” Eidenfrats adds.
“The world is ready for male birth control.”
Mental health
Pilates may improve heart and metabolic health in sedentary women, study finds

A four-week Pilates programme may improve heart, metabolic and stress measures in previously sedentary women, a small study suggests.
Pilates is a mind-body form of exercise that has been linked to better fitness, balance, posture, muscular endurance, mental wellbeing and quality of life in different groups.
Built around breathing, concentration, control, precision, centring and flow, Pilates is already used in physiotherapy, rehabilitation and preventive health. The new study looked at whether a structured four-week programme could affect cardiovascular, metabolic, body and stress-related measures in sedentary adult women.
The longitudinal study included 30 sedentary women split into two age groups, 30 to 40 and 50 to 60.
All participants completed a standardised, supervised Pilates programme lasting four weeks, with three sessions a week lasting 50 to 60 minutes.
Researchers measured resting heart rate, systolic and diastolic blood pressure, body mass index, abdominal circumference, fasting blood glucose and serum cortisol at the start and end of the programme.
Systolic and diastolic blood pressure are the top and bottom readings in a blood pressure test. Cortisol is a hormone linked to the body’s stress response.
The four-week Pilates programme was linked to improvements in cardiovascular, metabolic, body and neuroendocrine measures, although not every change reached statistical significance within each age group.
In the younger group, significant reductions were seen in heart rate, blood pressure, body mass index and fasting blood glucose after the intervention.
The reduction in blood pressure after the programme was significantly greater in the older group than in the younger group.
Older participants also showed a greater reduction in glucose and cortisol levels after the intervention than younger participants.
Analysis also found significant links between cardiovascular, metabolic and neuroendocrine changes.
In the younger group, this was particularly seen between heart rate and blood pressure responses.
In the older group, it was particularly seen between changes in body mass index and fasting glucose.
The findings suggest Pilates could be a useful multidimensional exercise approach for cardiometabolic health and stress regulation in previously sedentary women.
The researchers said the larger reduction in blood pressure seen in the older group may reflect a higher cardiometabolic burden at the start, leaving more room for improvement after the programme.
The greater reduction in fasting glucose and cortisol in older participants may similarly suggest that people with higher baseline metabolic and neuroendocrine dysfunction could benefit more from structured exercise such as Pilates.
Although Pilates is known to improve body composition through energy use, neuromuscular activation and support for healthier habits, the researchers said the fall in body mass index over four weeks is unlikely to be explained by Pilates alone.
They noted that participants were also told to avoid alcohol, sugar-containing products and sugar-sweetened drinks during the intervention, which may have contributed to the change.
In the younger group, the link between heart rate and blood pressure suggested coordinated cardiovascular responses after Pilates.
The researchers also found that cortisol appeared to be linked to blood pressure and body mass index, suggesting stress-related changes may be tied to cardiovascular and body regulation after the intervention.
In the older group, the link between body mass index and fasting glucose highlighted the relationship between body fat and metabolic regulation.
A positive link between blood pressure and body mass index in this group also suggested that improvements in vascular regulation may be associated with reductions in body mass.
Overall, the findings suggest Pilates-related physiological changes may involve interconnected cardiovascular, body, metabolic and neuroendocrine mechanisms, with different response patterns by age.
The study has important limits. It did not include a non-exercise control group, so it cannot prove Pilates directly caused the changes.
The sample size was also small, which limits how far the findings can be applied more widely.
The authors also noted that cortisol was measured using a single fasting morning sample, which limits conclusions about broader hypothalamic-pituitary-adrenal axis regulation, the system involved in the body’s stress response.
They said larger studies with longer follow-up will be needed to confirm whether Pilates causes these physiological changes over time.
Wellness
Being female not a universal stroke risk factor for patients with AF, study finds

Female sex may not raise stroke risk across all atrial fibrillation (AF) patients, with higher risk mainly seen in women aged 75 and older, a study suggests.
Researchers said stroke prevention for women with the condition should be more personalised, especially for patients under 75.
Dr Amitabh C Pandey, director of cardiovascular translational research at Tulane University School of Medicine, said: “For years, female sex has been included as a risk factor along with other factors such as high blood pressure and diabetes, meaning women were more likely to be prescribed anticoagulants.
“Our study shows younger women may not have as much added stroke risk as previously thought, while older women, particularly those over 75, appear to have a higher risk that deserves close attention.”
The new Tulane University study challenges a long-standing assumption in heart care that being female automatically increases stroke risk for patients with atrial fibrillation.
Atrial fibrillation, often called AF, is a common heart rhythm disorder that causes the heart to beat irregularly.
It is associated with a higher risk of stroke and is often treated with anticoagulants, also known as blood thinners.
The study found that stroke risk did not increase equally across all female patients with AF.
Instead, researchers said being female may act more as a risk modifier, with increased stroke risk seen primarily among women aged 75 and older or those with a greater burden of other health conditions.
Clinicians often use a scoring system to decide whether people with AF should be prescribed blood thinners.
The system gives points for factors including age, heart failure, diabetes, previous stroke, vascular disease and high blood pressure.
Women also receive one point for sex alone.
Researchers said this can mean women with AF become eligible for blood thinners earlier or more often than men with otherwise similar risk profiles.
While blood thinners can help prevent clot-related strokes, they can also increase the risk of bruising, prolonged bleeding, gastrointestinal bleeding and other serious complications.
The researchers analysed approximately 950,000 patients with AF using TriNetX, a large anonymised electronic health record database.
They compared stroke outcomes between male and female patients across three age groups: younger than 65, 65 to 74, and 75 and older.
Male and female patients were matched based on age, other health problems and whether they had been prescribed anticoagulation medicine.
Among patients younger than 75, the study found no significant difference in one-year stroke risk between men and women.
However, among patients aged 75 and older, women had a modest but statistically significant increase in stroke risk compared with men.
In patients aged 75 and older with no additional risk factors beyond age, women had about one additional stroke per 629 patients compared with their male counterparts.
The findings support growing interest in a newer AF risk score, known as CHA2DS2-VA, which removes sex as a standalone risk factor.
However, researchers said more studies are needed and medical guidance remains inconsistent.
Han Feng, assistant professor at Tulane University School of Medicine, said: “This general approach came from women being underrepresented in AFib trials and studies comprising only about one-third of study populations.
“Our study shows not all women with AFib have the same risk profile, and these decisions should be individualised.
Pandey said: “These findings highlight the need for modern tools and approaches that can personalise risk profiles to individuals.
“The goal is not to undertreat patients who need stroke prevention, but to better identify who is most likely to benefit from anticoagulation and who may be exposed to unnecessary risk.”
Hormonal health
Iron deficiency in women: The tiredness everyone normalises

Article produced in association with Spital Clinic
Feeling permanently tired has become so normal for so many women that most of us have stopped questioning it. But one of the most common reasons behind it is also one of the easiest to miss – and one of the most satisfying to fix.
The tiredness that gets explained away
There’s a particular kind of tired that a lot of women simply live with. The mid-afternoon slump that no amount of coffee touches. Needing an early night and still waking up flat. Putting it all down to work, kids, stress, age or hormones – anything except a cause you could actually do something about.
Often, though, that’s exactly what it is: a cause you could do something about. Low iron is one of the most common reasons women feel wiped out, and because it builds so gradually, it rarely announces itself. You don’t wake up one morning feeling different. You just slowly get used to running on less, until “exhausted” starts to feel like your baseline.
Why women are far more likely to run low
Iron is what your body uses to carry oxygen around in your blood. When levels fall, everything has to work a little harder to do the same job – which is why feeling tired is usually the very first thing you notice.
The reason this affects women so disproportionately is simple: periods. Every cycle carries a small iron cost, and over months and years that quietly adds up. Pregnancy adds to the demand too, when the body’s iron needs rise sharply.
But heavy periods are the big one – left unchecked, they can steadily drain your iron, which is why the NHS treats them as something worth looking into rather than just putting up with.
So if your periods sit on the heavier side, you’re not just dealing with the inconvenience in the moment – you may be slowly draining your iron stores at the same time, month after month.
The reassuring part is that heavy periods can be treated, so it’s worth having them looked at rather than soldiering on.
What low iron actually feels like
Tiredness is the headline, but it’s rarely the only clue. Low iron can show up as feeling breathless going up stairs you used to manage without thinking, a foggy, can’t-quite-focus feeling, looking paler than usual, or noticing your heart racing or thumping for no obvious reason.
Then there are the stranger signs people almost never connect to iron: brittle nails, more hair than usual collecting in the brush, restless legs at night, and – oddly – craving and crunching ice. On their own, each of these is easy to shrug off. Lined up together, they’re very often the same story.
Why it so often slips under the radar
Part of the problem is that none of these symptoms screams “iron.” They’re vague, they overlap with ordinary life, and they arrive slowly enough that you adjust without realising. Most of us are also remarkably good at minimising our own tiredness – we assume everyone feels like this, so there’s nothing to mention.
The result is that low iron can go unaddressed for years, not because it’s hard to find, but because nobody thinks to look. It’s a genuinely common, genuinely treatable issue that quietly chips away at how good you’re allowed to feel.
When “heavy” periods are actually heavy
Here’s the tricky bit: most women have no real benchmark for what counts as heavy, because the only period we ever experience is our own. A useful rule of thumb is needing to change a pad or tampon every hour or two, bleeding that lasts longer than seven days, or passing clots bigger than a 10p coin.
NICE frames it even more usefully: periods count as heavy if they’re getting in the way of your life – physically, emotionally or socially. You don’t have to measure anything. If you’re planning your week around your period, doubling up on protection, or it’s leaving you drained, that’s reason enough to take it seriously.
And the good part is they don’t have to be permanent. If yours have crept up over time, getting them under control is worth it in its own right – and it often tackles the iron problem at its source, rather than topping you up only to lose it again next month.
How you actually find out
You can’t tell your iron levels from how you feel. Plenty of women feel rough with results that look “borderline fine,” and some feel reasonably okay while their reserves are already running low.
The only way to know is a straightforward blood test that checks both your blood count and your ferritin – the marker that reflects how much iron you’ve actually got stored away.
Ferritin is the one that matters here, because it tends to drop first, before a standard anaemia test would flag anything as wrong. That’s exactly why a woman can be told her bloods are “normal” and still feel exhausted: the headline number looks acceptable, but the reserves sitting behind it have been running down for a while.
The good news: it’s very fixable
This is the part worth holding onto. Iron deficiency is one of the more rewarding things to put right. The NHS approach is usually a course of iron tablets over several months to rebuild your stores, paired with a source of vitamin C – even just a glass of orange juice – to help your body absorb them properly.
Alongside that, dealing with whatever’s causing the loss in the first place is what stops you ending up back at square one.
Most women start to notice the difference within a few weeks, often well before their levels are fully restored. The fog lifts, the stairs get easier, and the version of “normal” you’d quietly resigned yourself to turns out not to have been normal at all.
The takeaway
The exhaustion so many women treat as a fixed fact of life frequently isn’t one. Low iron is common, it’s quick to check, and it’s straightforward to put right – but only if someone actually looks for it.
If you’ve been tired for longer than you can remember, especially if your periods are heavy, it’s worth getting your iron checked rather than explaining it away for another year. Speaking to a GP is usually all it takes to get that started – and more often than not, the fix turns out to be far simpler than the months of tiredness would suggest.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS and NICE information as at May 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with Spital Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
Menopause2 weeks agoPerimenopause misinformation ‘putting women at risk’
Hormonal health3 weeks agoNHS urged to update website following renaming of PCOS
Hormonal health4 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
News1 week agoWomen still being failed when they reach menopause, experts say
Entrepreneur2 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Diagnosis4 weeks agoArtera receives FDA Clearance for breast cancer platform
News1 week agoThree menopause innovators shortlisted for Femtech World Award
Fertility3 weeks agoAI could transform ovarian care through personalisation, study finds













